{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/acne-vulgaris/how-up-to-date-is-this-topic/update/","result":{"pageContext":{"chapter":{"id":"501eff80-f5ab-5966-b79a-791cec9fcf7c","slug":"update","fullItemName":"Update","depth":2,"htmlHeader":"<!-- begin field 157927ba-1053-46bb-91d0-fa032158d54e --><h2>Update</h2><!-- end field 157927ba-1053-46bb-91d0-fa032158d54e -->","summary":null,"htmlStringContent":"<!-- begin item ef29b6b4-6461-4386-afc1-e27aeb03ce0f --><!-- end item ef29b6b4-6461-4386-afc1-e27aeb03ce0f -->","topic":{"id":"4f10413c-64a7-5bb3-9003-1093b58e5700","topicId":"7737f6eb-1907-461e-a10b-166056e652b7","topicName":"Acne vulgaris","slug":"acne-vulgaris","lastRevised":"Last revised in August 2020","chapters":[{"id":"c13b5a16-bcf3-5b36-8dce-af226250264d","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"318cce93-72af-5473-9c96-2577e69df14c","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"6aac7922-c920-5394-bc2c-08ae3e93e4c5","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"b6ea59d7-e11c-59ba-ae3a-d12eda1c224b","slug":"changes","fullItemName":"Changes"},{"id":"501eff80-f5ab-5966-b79a-791cec9fcf7c","slug":"update","fullItemName":"Update"}]},{"id":"017f5393-8a9f-5cdb-9799-d9c32c6b50e9","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"32769738-e7d1-5c7a-a6ac-7e242b6ad659","slug":"goals","fullItemName":"Goals"},{"id":"60cde7a9-d789-5629-a7d6-e14882c6caf9","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"f91e328f-4d37-5a01-ab6d-edf7165acdaf","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"01961474-a4a0-5330-bc03-aca2c93fd7ed","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"867bb680-22ea-5d29-88b0-f219f9e8dae8","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"8447443c-c6e1-5af4-ab33-68aa460c97b0","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"10279ff1-6a1f-5af9-97b1-73405139911f","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"13ced928-40f6-593c-8ae8-3d619c885e2e","slug":"definition","fullItemName":"Definition"},{"id":"290d67e9-4d5f-5a03-bafc-46380a14e964","slug":"causes","fullItemName":"Causes"},{"id":"2c90cfb7-ff4f-535b-b067-7b291de8de21","slug":"prevalence","fullItemName":"Prevalence"},{"id":"5665dddd-4418-59f5-8480-8d73bc88b392","slug":"complications","fullItemName":"Complications"},{"id":"8e63da8e-8783-584a-962f-77fc8f5cda7c","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"cac20ff4-4d28-5a3d-ab66-5ad66ea6485d","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"318b12a5-f38e-5aa0-866d-258e0bc4606b","slug":"clinical-features","fullItemName":"Clinical features"},{"id":"00cb6f19-98f0-5279-8ca3-56e9898a856b","slug":"assessment","fullItemName":"Assessment"},{"id":"9a6b352b-2522-507b-baee-3746ed6c5fc1","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"93060cf3-048d-55d8-b979-1ee7c8b333d0","fullItemName":"Management","slug":"management","subChapters":[{"id":"8708236c-483d-548a-bcbb-ece4a63d3ef2","slug":"primary-care-management","fullItemName":"Scenario: Primary care management"}]},{"id":"ff879f6d-4cca-54e7-b137-1bea3673664f","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"9c9958ec-2ef2-5cdd-8066-9039ba251071","slug":"benzoyl-peroxide","fullItemName":"Benzoyl peroxide"},{"id":"6d9ac0d3-8378-55b8-b6dc-17fb87472c20","slug":"topical-retinoids","fullItemName":"Topical retinoids"},{"id":"b3431b25-388f-5ae4-9ae3-fe13143c5d26","slug":"topical-antibiotics","fullItemName":"Topical antibiotics"},{"id":"9ca57669-ad06-5179-885d-5b8063e1323f","slug":"azelaic-acid","fullItemName":"Azelaic acid"},{"id":"8ae4cfcf-ffa5-5d2f-b469-369a52c50963","slug":"oral-antibiotics","fullItemName":"Oral antibiotics"},{"id":"dd897071-f76b-5e49-9c2d-e98f4b853afa","slug":"combined-oral-contraceptives","fullItemName":"Combined oral contraceptives"}]},{"id":"1a455bee-cdcd-5bfe-ac3c-92ebf7dc4f1b","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"c326d983-7898-5757-a2dd-0324dc5bca9a","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"7efc9e19-3f3c-5fe4-86af-6645e982294d","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"5133582b-9a2b-5faf-a3be-a014b639deef","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"10179a08-abca-5ecd-982e-b1147cb710a3","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"25e71f93-96a6-5694-a7be-371938647a37","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"2adb6ee6-1991-50db-bb70-4a7b3d113064","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"9f2f3c9d-3968-50fd-88cb-555214f14d6b","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"6aac7922-c920-5394-bc2c-08ae3e93e4c5","slug":"how-up-to-date-is-this-topic","fullItemName":"How up-to-date is this topic?"},"subChapters":[{"id":"5df0d9d5-f530-5a6f-afe3-bf7fc319192e","slug":"new-evidence","fullItemName":"New evidence","depth":3,"htmlHeader":"<!-- begin field 81ee98f7-7347-4f51-8201-6e80bff20058 --><h3>New evidence</h3><!-- end field 81ee98f7-7347-4f51-8201-6e80bff20058 -->","summary":null,"htmlStringContent":"<!-- begin item 40273a28-cff6-47bd-a684-1a1ffc2a6225 --><!-- begin field 30626176-0cc0-4f0d-a084-0653d6012862 --><h3>Evidence-based guidelines</h3><!-- end field 30626176-0cc0-4f0d-a084-0653d6012862 --><!-- begin field 8923f864-535b-4777-8786-76e28a6e1740 --><p>No new evidence-based guidelines published since 1 March 2018.</p><!-- end field 8923f864-535b-4777-8786-76e28a6e1740 --><!-- begin field df7d9f61-551f-4e8e-9db5-4bfd1db699f1 --><h3>HTAs (Health Technology Assessments)</h3><!-- end field df7d9f61-551f-4e8e-9db5-4bfd1db699f1 --><!-- begin field f8c94850-1a41-4641-86fb-0ae1b65de1db --><p>No new HTAs since 1 March 2018.</p><!-- end field f8c94850-1a41-4641-86fb-0ae1b65de1db --><!-- begin field 701c9d3a-da1d-4b31-a50d-b346ce71673b --><h3>Economic appraisals</h3><!-- end field 701c9d3a-da1d-4b31-a50d-b346ce71673b --><!-- begin field ecf903c0-d402-45b7-9012-58b97767476e --><p>No new economic appraisals relevant to England since 1 March 2018.</p><!-- end field ecf903c0-d402-45b7-9012-58b97767476e --><!-- begin field 0a83f8c1-eac6-4d2c-a6b2-7c038ce1f330 --><h3>Systematic reviews and meta-analyses</h3><!-- end field 0a83f8c1-eac6-4d2c-a6b2-7c038ce1f330 --><!-- begin field 0f9e7140-eca6-47cd-93da-1faf5daa0a74 --><p>No new systematic reviews or meta-analyses since 1 March 2018.</p><!-- end field 0f9e7140-eca6-47cd-93da-1faf5daa0a74 --><!-- begin field fc704e66-e6b8-4d10-b66f-47603aba0e2a --><h3>Primary evidence</h3><!-- end field fc704e66-e6b8-4d10-b66f-47603aba0e2a --><!-- begin field 447149cf-8c75-4b66-aa0c-b8bd0e52b14f --><ul><li>Liu, H., Yu, H., Xia, J, et al. (2020) <em>Topical azelaic acid, salicylic acid, nicotinamide, sulphur, zinc and fruit acid (alpha-hydroxy acid) for acne.</em> Cochrane Library. <a href=\"https://www.cochranelibrary.com/\" data-hyperlink-id=\"6fb166e0-d2ca-43b0-8ffd-ac3d00b29949\">www.cochranelibrary.com</a> [<a href=\"https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011368.pub2/full\" data-hyperlink-id=\"ed6793d4-16ee-4c0d-90d3-ac3d00b29a23\">Free Full-text</a>]</li></ul><!-- end field 447149cf-8c75-4b66-aa0c-b8bd0e52b14f --><!-- end item 40273a28-cff6-47bd-a684-1a1ffc2a6225 -->","subChapters":[]},{"id":"7493cd32-9239-53de-b798-daf462962d1d","slug":"new-policies","fullItemName":"New policies","depth":3,"htmlHeader":"<!-- begin field faa8bb9c-244b-4a1c-8b57-c17d37f99d03 --><h3>New policies</h3><!-- end field faa8bb9c-244b-4a1c-8b57-c17d37f99d03 -->","summary":null,"htmlStringContent":"<!-- begin item 84ae40fd-f02f-4b1d-8517-8d9c8e90b021 --><!-- begin field 211cf780-bb7c-408f-a76b-4fd4803967aa --><p>No new national policies or guidelines since 1 March 2018.</p><!-- end field 211cf780-bb7c-408f-a76b-4fd4803967aa --><!-- end item 84ae40fd-f02f-4b1d-8517-8d9c8e90b021 -->","subChapters":[]},{"id":"a984745a-23c8-58ec-918f-d57cfd362afa","slug":"new-safety-alerts","fullItemName":"New safety alerts","depth":3,"htmlHeader":"<!-- begin field 9b1fa2d6-7895-410c-ad60-3e71c15e4ed6 --><h3>New safety alerts</h3><!-- end field 9b1fa2d6-7895-410c-ad60-3e71c15e4ed6 -->","summary":null,"htmlStringContent":"<!-- begin item 20344746-aae8-4120-b8e7-5c86aef1224f --><!-- begin field 8ca55045-243f-4fee-b518-8058964302d2 --><p>No new safety alerts since 1 March 2018.</p><!-- end field 8ca55045-243f-4fee-b518-8058964302d2 --><!-- end item 20344746-aae8-4120-b8e7-5c86aef1224f -->","subChapters":[]},{"id":"8f689d8d-888e-5a9d-8f8a-790c278993ab","slug":"changes-in-product-availability","fullItemName":"Changes in product availability","depth":3,"htmlHeader":"<!-- begin field 92fa3a92-e689-4f1d-a7af-7f3e1a457e46 --><h3>Changes in product availability</h3><!-- end field 92fa3a92-e689-4f1d-a7af-7f3e1a457e46 -->","summary":null,"htmlStringContent":"<!-- begin item 28564c5b-d79a-4f1c-b62c-e0cd37295fdb --><!-- begin field c0860036-83ef-4256-8c08-bf9b24681bd5 --><p>Epiduo 0.3%/2.5% (adapalene/benzoyl peroxide) gel is licensed for the cutaneous treatment of acne vulgaris, when comedones, numerous papules and pustules are present. For more information, see <a href=\"https://www.medicines.org.uk/emc/product/11180/smpc\" data-hyperlink-id=\"65c003c1-bf7c-492d-9e9c-ab9200b4e20a\">here</a>.</p><!-- end field c0860036-83ef-4256-8c08-bf9b24681bd5 --><!-- end item 28564c5b-d79a-4f1c-b62c-e0cd37295fdb -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}